Biomerica, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.1M
- Price
- $1.66
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.34%
- Volume
- 6.1K
Quote data as of 6:13 AM ET
About
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Quick stats
Shares outstanding3.1M
Computed float2.6M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000073290
Websitehttps://www.biomerica.com
AI Summary
AI-generated1mo agostandardbullishoperations updateBiomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Biomerica signed a Master Services Agreement with a confidential life sciences partner to develop proprietary IVD assays.
The deal carries an initial target fee of $1.75 million, to be earned over a three-year term with automatic renewals.
Management highlights that this leverages existing infrastructure and scientific capabilities, creating a capital-efficient revenue stream alongside its primary inFoods® IBS product.
Red flags
- Partner identity is confidential
- Revenue recognition is milestone-based; no revenue recognized until SOWs are executed and deliverables accepted
- Forward-looking statements warn of risks including SOW non-execution and program cancellation